Assembly Biosciences financials
$23.48−0.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0.00 | $6.3M | $79.1M | $16.0M | $14.8M | $9.0M | $0.00 |
| Gross profit | $72.3M | $28.5M | $7.2M | $0.00 | $6.3M | $79.1M | $16.0M | $14.8M | $9.0M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M | -$64.8M | -$102.7M | -$92.7M | -$52.8M | -$45.3M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | -$129.9M | -$62.2M | -$97.6M | -$90.8M | -$42.8M | -$44.3M |
| Net margin | −8.5% | −140.9% | −854.8% | — | −2076.4% | −78.6% | −611.6% | −613.0% | −474.7% | — |
| Diluted EPS | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-36.00 | $-21.00 | $-44.64 | $-47.76 | $-28.92 | $-30.84 |
| EBITDA | -$12.0M | -$45.3M | -$64.2M | -$93.6M | -$90.0M | -$64.1M | -$104.0M | -$92.3M | -$52.6M | -$45.2M |
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M | -$64.7M | -$84.1M | -$65.0M | $1.9M | -$34.9M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M | -$65.2M | -$85.6M | -$65.3M | $995.0K | -$35.0M |
| Diluted shares | 11.2M | 6.0M | 4.6M | 4.0M | 3.6M | 3.0M | 2.2M | 1.9M | 1.5M | 1.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $58.5M | $38.3M | $19.8M | $52.4M | $45.6M | $59.4M |
| Short-term investments | $189.7M | $73.7M | $110.4M | $39.2M | $101.0M | $157.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M | $283.3M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M | $42.7M |
| Shareholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M | $240.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology